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Abstract
Purpose Radiosurgery requires precise lesion localiza-
tion. Fiducial markers enable lesion tracking, but compli-
cations from insertion may occur. The purpose of this study
was to describe complications of ﬁducial marker insertion
into pulmonary lesions.
Materials and Methods Clinical and imaging records of
28 consecutive patients with 32 lung nodules or masses
who underwent insertion of a total of 59 ﬁducial markers
before radiosurgery were retrospectively reviewed.
Results Eighteen patients (67%) developed a pneumotho-
rax,andsixpatients(22%)requiredachesttube.Theratesof
pneumothorax were 82% and 40%, respectively, when
18-gauge and 19-gauge needles were used for marker
insertion (P = 0.01). Increased rate of pneumothorax was
alsoassociatedwithtargetingsmallerlesions(P = 0.03)and
tumors not in contact with the pleural surface (P = 0.04).
Atotalof11ﬁducials(19%)migratedafterinsertionintothe
pleural space (10 markers) or into the airway (1 marker).
Migration was associated with shorter distances from pleura
to the marker deposition site (P = 0.04) and with ﬁducial
placement outside of the target lesion (P = 0.03).
Conclusion Fiducial marker placement into lung lesions
is associated with a high risk of pneumothorax and a risk of
ﬁducial migration.
Keywords Fiducial marker  Complications 
Pneumothorax  Migration  Lung neoplasm
Introduction
Radiosurgery was ﬁrst developed for delivery of high
radiation doses to well-circumscribed brain metastases
[1–4]. Consistent doses could be delivered to these lesions
because of their relatively stationary position. When this
technique is modiﬁed to treat tumors located elsewhere in
the body, accurate delivery of consistent radiation doses
becomes difﬁcult as a result of tumor motion during res-
piration. This problem is especially evident in the lung.
Commercially available radiosurgery systems rely on
differences in tissue density for lesion tracking. The
inherent difference in density between the tumor and the
surrounding tissues may be sufﬁcient for the system to
track lesion movement during respiration. When tumor
tissue density is not sufﬁciently differentiated from the
density of surrounding normal parenchyma, a metallic
ﬁducial marker placed within or adjacent to the lesion is
required for accurate radiotherapy targeting.
Complications from ﬁducial marker insertion have been
reported, including pneumothorax in 33–68% of patients as
well as bleeding [5–7]. Fiducial markers may also migrate
into the pleural space, the airway, or into the vascular
structures. The purpose of this study was to describe
complications of ﬁducial marker placement into pulmonary
lesions.
Materials and Methods
This study was approved by the Committee on Human
Research at our institution. Informed consent requirement
was waived. Records of 28 consecutive patients (15 men,
13 women; mean age 64 years) referred to our institu-
tion for percutaneous ﬁducial marker placement before
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CA) between December 2004 and October 2009 were
retrospectively reviewed. Indications for radiosurgery
included unresectable non-small-cell lung carcinoma
(n = 14 patients) and metastatic disease to the lungs from
colorectal carcinoma (n = 5), soft tissue sarcoma (n = 5),
melanoma (n = 2), renal-cell carcinoma (n = 1), and
lymphoma (n = 1). One male patient with two nodules in
the left lung underwent a computed tomographic (CT)-
guided biopsy of one of the nodules 24 h before ﬁducial
placement. This patient developed a pneumothorax at the
time of biopsy, which was treated by insertion of a chest
tube. The chest tube remained in place at the time of the
ﬁducial placement. Data from this patient were therefore
excluded from the analysis of pneumothorax-related risk
factors, but were included in the analysis of ﬁducial
migration.
At the request of our institution’s radiation oncologists,
between one and three ﬁducials, each measuring 1.2 mm
by 3 mm (Alpha-Omega Services, Bellﬂower, CA), were
placed within or adjacent to each lesion. The number of
ﬁducials used in each case was at the discretion of
the interventional radiologist performing the procedure.
In general, lesions greater than 3 cm in diameter were
targeted withtwoorthreemarkers,whereasoneﬁducialwas
used for nodules less than 3 cm in diameter. The ﬁducials
did not have to be positioned within the lesion. Marker
placement within 1 cm of the lesion was acceptable for
targeting. If a ﬁducial migrated away from its intended
location, additional markers were inserted until at least one
marker remained within or adjacent to the target lesion.
A total of 59 ﬁducial markers were placed. In four
patients, two lesions located in the same lung were tar-
geted; one lesion was targeted in the remainder of the
patients. Because marker migration occurred upon inser-
tion in six patients, up to seven ﬁducials (range 1–7) were
required to achieve durable lesion targeting with at least
one marker. Between one and seven ﬁducials were used for
each lesion (median 1), and between one and seven ﬁdu-
cials were used for each patient (median 2). Lung biopsies
were not performed before ﬁducial placement.
In each insertion procedure, CT was used to guide a
15-cm, 18-gauge double-wall Chiba needle (18 patients;
Cook, Bloomington, IL) or a 15-cm 19-gauge Temno
guiding double-wall needle (10 patients; Cardinal Health,
Dublin, OH) into the lung lesion (Fig. 1). Choice of needle
gauge was at the discretion of the physician operator. After
the needle was placed in the lesion, the marker was
delivered through the needle with a 0.035-inch straight
guide wire (Long-Tip; Cook) or the needle stylet. After the
procedure, patients were followed with chest radiographs at
hourly intervals for 2 h. Chest tube insertion was per-
formed in patients with a pneumothorax and one or more of
the following clinical features: dyspnea, oxygen saturation
of \92% on room air, pneumothorax exceeding 25% of
hemithorax volume, or increasing pneumothorax on serial
radiographs.
Patient records including CT scans of the thorax, chest
radiographs, and clinic notes were retrospectively reviewed.
Follow-up chest CT scans and/or chest radiographs were
available for all patients. Follow-up period ranged from 1 to
46 months (mean 11.9 months). Preprocedure CT images
were used to determine lesion volume and to look for
radiographic evidence of emphysema (presence of bullae or
parenchymal lucencies located in the typical centrilobular,
panlobular, or paraseptal distribution pattern). Presence or
absence of emphysema was also determined from chart
reviews, which were focused on clinic notes, hospital dis-
charge summaries, and on the results of pulmonary function
tests. Patients were categorized as having emphysema if
they carried this diagnosis in the medical record or if there
was evidence of emphysema on CT. Postprocedural CT
scans were also evaluated for the length of needle trajectory
through lung parenchyma, ﬁducial marker position in
relation to the lesion, and development of a pneumothorax.
The number of needle adjustments within the lung paren-
chyma (deﬁned as any needle manipulation after crossing
the pleura and documented by the procedural CT) before
deposition of each ﬁducial was also determined. Needle
adjustments before crossing the pleura were not counted.
Targeting of each lesion required a median of one adjust-
ment (range 1–8). The location of the ﬁducial markers on
follow-up CT scans and chest radiographs was compared to
their location on the initial scans in order to determine
whether ﬁducial migration had occurred.
Our study focused on the rates of pneumothorax and
ﬁducial migration as well as on elucidation of potential risk
factors that may lead to these complications. Patients with
and without these complications were compared with
regard to several factors including lesion volume, length of
needle trajectory through the lung parenchyma, number of
ﬁducials inserted in a given lesion, number of needle
adjustments within the lung parenchyma required for
ﬁducial positioning, lesion location (upper or lower lung
zone), lesion location in relation to the pleural surface,
Fig. 1 Standard apparatus for ﬁducial insertion: 15-cm, 18-gauge
double-wall needle and a gold seed ﬁducial marker (arrow)
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lesion (inside or outside the target lesion), presence or
absence of pneumothorax before ﬁducial insertion, pres-
ence or absence of emphysema (on the basis of CT and
clinical records), violation of a ﬁssure, and needle gauge.
The associations of the above factors with ﬁducial place-
ment-related complications including pneumothorax, chest
tube placement, and ﬁducial migration were analyzed by
multivariate generalized estimating equation models. This
modeling approach appropriately accounted for the statis-
tical dependence among multiple ﬁducials and multiple
lesions in the same individual. All analyses were conducted
by SAS software, version 9.2 (SAS Institute, Cary, NC).
All results were reported as P values, with P = 0.05
serving as a threshold for statistical signiﬁcance. Lesion
volumes were calculated by multiplying the cross-sectional
area of each section by the section thickness and adding the
individual section volumes. Length of needle trajectory
through the lung parenchyma was measured at the point of
ﬁducial deposition as the distance between needle tip and
pleural surface. Because 10 ﬁducials migrated immediately
or soon after their insertion, this measurement was used to
estimate the distance from the ﬁducial insertion site to the
pleural surface.
Results
Eighteen of 27 patients (67%) developed a pneumothorax
as a result of the ﬁducial marker insertion. Pneumothoraces
were detected immediately after placement of the ﬁducials
on the chest CT images (Fig. 2). Of the 18 patients with
pneumothorax, six (33% of patients with pneumothorax;
22% of all patients) required chest tube placement because
of clinical symptoms or increasing size of the pneumo-
thorax. Increased rates of pneumothorax and chest tube
insertion were found when 18-gauge needles were used for
ﬁducial marker placement (Table 1). Fourteen of 17
patients (82%) developed pneumothoraces after ﬁducial
insertion through an 18-gauge needle, compared to 4 of 10
patients (40%) in whom 19-gauge needles were used
(P = 0.01). In addition, the rate of postprocedure pneu-
mothorax was 40% for lesions extending to the pleural
surface, which was signiﬁcantly lower than the 80%
pneumothorax rate for lesions that did not contact the
pleura (P = 0.04). Last, the development of postprocedure
pneumothorax was associated with targeting smaller
lesions (P = 0.03).
Statistical analysis demonstrated an incremental 8%
increase in the risk of pneumothorax for every 10 cm
3
decrease in lesion volume. A total of 11 ﬁducial markers
(19%) had migrated after placement. Fiducial migration
was observed while targeting six lesions in six individual
patients. The number of displaced ﬁducials ranged from
one to ﬁve per patient (median 1). In four patients, dis-
placed ﬁducials were found in the pleural space on post-
placement CT images obtained within several minutes of
insertion. In one patient, the ﬁducial remained within the
lesion on the follow-up chest radiographs obtained up to
2 h after insertion. However, CT of the chest obtained
Fig. 2 Computed tomographic
images demonstrating ﬁducial
marker placement. The needle
is inserted into the lesion
(a, arrows), and the ﬁducial
marker (arrowhead)i s
deposited within the middle of
the lesion (b, arrows). In this
case, there was a postprocedure
pneumothorax (c, arrows),
which was subsequently treated
with a chest tube (d, arrows)
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1236 days after marker placement demonstrated that the
ﬁducial had migrated into the pleural space (Fig. 3). This
necessitated insertion of a second marker within the lesion.
This ﬁducial remained within the nodule for at least
1 month after insertion, allowing the patient to receive a
full course of radiosurgery. In the sixth patient, the marker
was noted to have migrated into the contralateral airway
immediately after placement. Subsequently, the patient
experienced a bout of coughing, after which the marker
was no longer seen on the CT images; it was likely
expectorated.
Imaging follow-up with chest CT and/or chest radio-
graphs was available for 1 to 46 months for all patients
(mean 11.9 months). Fiducial marker migration was not
detected beyond 6 days after placement. Statistical analysis
(Table 2) demonstrated an association between the
increased rate of ﬁducial migration and shorter distance
from pleura to the marker deposition site (P = 0.04), as
well as with ﬁducial placement outside of the target lesion
(P = 0.03). No association was found between ﬁducial
migration and lesion volume. In addition, ﬁducial migra-
tion was not associated with marker insertion through an
iatrogenic pneumothorax.
Discussion
In this series, ﬁducial marker insertion in lung lesions
resulted in a pneumothorax in 67% of patients. The rates
of pneumothorax and subsequent chest tube insertion
reported here are higher than those described in the liter-
ature (45 and 33%, respectively; [6, 7]). We demonstrated
increased rates of pneumothorax and chest tube insertion
when 18-gauge guiding needles were used for ﬁducial
marker insertion. Only 19-gauge needles were used for
marker placement in other published series [6]. In a recent
Table 1 Evaluation of potential risk factors for association with development of a pneumothorax (PTX)
Factor Patients
without PTX (n = 9)
Patients with
PTX (n = 18)
PTX and chest tube
(n = 6)
P value
a P value
b
Lesion volume (mean ± SD) 103 ± 161 cm
3 28 ± 43 cm
3 21 ± 23 cm
3 0.03 0.25
Needle trajectory length (mean ± SD) 2.8 ± 1.8 cm 3.0 ± 1.7 cm 2.4 ± 1.4 cm 0.07 0.82
No. of markers, median (range) 1 (1–3) 1 (1–7) 3 (1–7) 0.35 0.16
No. of needle adjustments, median (range) 3 (1–6) 1 (1–8) 1 (1–8) 0.61 0.75
Lesion location, n (%)
Upper lung zone 2 (20%) 7 (35%) 3 (50%) 0.43 0.74
Lower lung zone 8 (80%) 13 (65%) 3 (50%)
Lesion relationship to pleura, n (%)
Contacts pleura 6 (60%) 4 (20%) 1 (17%) 0.04 0.01
No pleural contact 4 (40%) 16 (80%) 5 (83%)
Emphysema present, n (%) 5 (56%) 5 (28%) 3 (50%) 0.19 0.83
Fissure crossed, n (%) 0 (0%) 1 (5%) 1 (17%) 0.92 0.95
Needle used, n (%)
18 gauge 3 (33%) 14 (78%) 5 (71%) 0.01 0.03
19 gauge 6 (67%) 4 (22%) 2 (29%)
a Comparison between patients with and without PTX
b Comparison between patients without PTX and patients with an enlarging or a symptomatic PTX that necessitated insertion of a chest tube
Fig. 3 Computed tomographic
(CT) images demonstrating
ﬁducial marker migration.
Immediate postinsertion CT
scan (a) showing the ﬁducial
marker (arrowhead) within the
lesion (arrows). On a scan
6 days later (b), the marker was
not seen in the lesion (arrows).
The marker was located in the
costophrenic sulcus of the
pleural space
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123large retrospective series of percutaneous lung biopsies,
Geraghty et al. [8] also demonstrated a signiﬁcantly higher
risk of pneumothorax associated with the use of coaxial
18-gauge needles compared to 19-gauge needles. Use of a
larger-bore needle may have led to a larger defect in the
pleura. In addition, the 18-gauge needles may be stiffer and
less prone to movement during respiration, leading to lar-
ger tears in the pleura. The analysis also showed that
patients who developed a pneumothorax tended to have
smaller lesions. Larger lesions may be more likely to
extend to the pleura and allow needle passage into the
lesion without traversing the aerated lung. We were not
able to demonstrate that targeting smaller lesions required a
larger number of needle adjustments within the lung
parenchyma.
The pneumothorax rate after ﬁducial marker insertion
reported here is also higher than the 8–64% rate of this
complication after percutaneous lung biopsy [8, 9]. Fur-
thermore, the 22% rate of chest tube insertion reported here
is beyond the suggested threshold of 10% for lung biopsies
according to the Quality Improvement Guidelines for
Image-Guided Percutaneous Biopsy in Adults [10]. There
are several potential reasons for these differences, includ-
ing the use of 18-gauge needles (versus smaller needles for
performing biopsies) and longer times that the needle
remains in the lung parenchyma (as a result of the addi-
tional time required for ﬁducial marker insertion).
Fiducial migration after placement was encountered
after insertion of 19% of the markers. Our analysis reveals
that the rate of marker migration was higher when ﬁducials
were deposited outside the target lesion and when the
markers were placed in close proximity to the pleural
surface. We found no association between ﬁducial migra-
tion and targeting smaller lesions or with marker inser-
tion through an iatrogenic pneumothorax. Fiducials were
most commonly dislodged at the time of or soon after
insertion. Once an appropriate marker position was docu-
mented on the postplacement CT, marker migration
seemed uncommon.
Our study has several limitations. The study was retro-
spective, limiting the clinical information available for
analysis. However, all preprocedure and follow-up imaging
studies were available for review. In addition, the small
sample size may have limited our ability to detect addi-
tional risk factors for development of a pneumothorax and
for ﬁducial migration.
The rate of complications after ﬁducial marker insertion
described in this study has serious implications. The 67%
rate of pneumothorax, the 22% rate of chest tube insertion,
and the 19% rate of seed migration are high. These com-
plication rates may be reduced by altering the insertion
technique or by changing the type of the ﬁducial marker
used for lesion tracking. The dimensions of the currently
used ﬁducial markers (1.2 by 3 mm) mandate the use of at
least a 19-gauge needle. A smaller marker size may make
the insertion procedure safer.
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